NDLI: A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer.

Please wait, while we are loading the content...

Metabolic and prostate-specific antigen response after abiraterone acetate withdrawal: a new clinical scenario for castration-resistant prostate cancer?

Influence of body mass index and smoking on the long-term survival of patients with renal cell cancer.

Intermediate-term outcomes of robot-assisted laparoscopic nephroureterectomy in upper urinary tract urothelial carcinoma.

Yonsei criteria: a new protocol for active surveillance in the era of robotic and local ablative surgeries.

Differing risk of cancer death among patients with pathologic T3a renal cell carcinoma: identification of risk categories according to fat infiltration and renal vein thrombosis.

Glasgow prognostic score as a prognostic factor in metastatic castration-resistant prostate cancer treated with docetaxel-based chemotherapy.

Adjuvant treatment for resected renal cell carcinoma: are all strategies equally negative? Potential implications for trial design with targeted agents.

Prognostic effect of sarcomatoid dedifferentiation in patients with surgically treated renal cell carcinoma: a matched-pair analysis.

Paraneoplastic palmar fasciitis and polyarthritis syndrome in a patient with advanced prostate cancer.

A better understanding of lymphatic drainage of the prostate with modern imaging and surgical techniques.

A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer.

A randomized phase II trial evaluating different schedules of zoledronic acid on bone mineral density in patients with prostate cancer beginning androgen deprivation therapy.

Stem cell origin of testicular seminoma.

Introduction and first clinical application of a simplified immunohistochemical validation system confirms prognostic impact of KI-67 and CK20 for stage T1 urothelial bladder carcinoma: single-center analysis of eight biomarkers in a series of three hundred six patients.

'Real world' treatment of metastatic renal cell carcinoma in a joint community-academic cohort: progression-free survival over three lines of therapy.

The impact of frozen section analysis during partial nephrectomy on surgical margin status and tumor recurrence: a clinicopathologic study of 433 cases.

Technologic developments in the field of photonics for the detection of urinary bladder cancer.

A phase II safety and efficacy study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer.

Luteinizing hormone--releasing hormone agonists: a quick reference for prevalence rates of potential adverse effects.

Use of denosumab for renal cell carcinoma-associated malignant hypercalcemia: a case report and review of the literature.

Renal cell carcinoma metastasis to a contralateral oncocytoma in a patient presenting with bilateral synchronous renal tumors.

Cancer of the Indiana Pouch: a case report and review of the literature.

Surrogate end points and postprogression survival in renal cell carcinoma: an analysis of first-line trials with targeted therapies.

Efficacy of oxaliplatin plus pemetrexed in chemotherapy pretreated metastatic castration-resistant prostate cancer.

Year: 2013 Volume: 11 Issue: 3

Year: 2013 Volume: 11 Issue: 2

Year: 2013 Volume: 11 Issue: 1

Year: 2012 Volume: 10

A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Armstrong, Andrew J. Shen, Tong Halabi, Susan Kemeny, Gabor Bitting, Rhonda L. Kartcheske, Patricia Embree, Elizabeth Morris, Karla Winters, Carolyn Jaffe, Tracy Fleming, Mark George, Daniel J.
Description	Author Affiliation: Armstrong AJ ( Duke Cancer Institute and the Duke Prostate Center, Duke University, Durham NC)
Abstract	BACKGROUND: Phosphatase and tensin homologue (PTEN) loss is common in advanced prostate cancer, leading to constitutive activation of the PI3 kinase pathway. Temsirolimus blocks mammalian target of rapamycin (mTOR)/target of rapamycin complex 1 (TORC1), a key signaling node in this pathway; its activity in men with advanced castration-resistant metastatic prostate cancer (mCRPC) is unknown. METHODS: We conducted a single-arm trial of weekly intravenous temsirolimus administration in men with chemorefractory mCRPC who had ≥ 5 circulating tumor cells (CTCs) at baseline. The primary end point was the change in CTCs at 8 weeks; secondary end points were composite progression-free survival (PFS) (excluding prostate-specific antigen [PSA]), PSA and radiographic response rates, safety, and survival. At PSA/CTC progression, an anti-androgen could be added while continuing temsirolimus. RESULTS: Eleven patients were accrued out of a planned 20; the trial was stopped prematurely because of lack of efficacy/feasibility. Median age was 61 years, with 55% African-Americans and 36% Caucasian patients. Median baseline PSA level was 390 ng/dL, median baseline number of CTCs was 14 cells; 50% of patients had pain, and 63% had undergone ≥ 2 previous chemotherapy regimens. Median CTC decline was 48% and 3 patients experienced decline in CTCs to < 5. However, 73% of men had a persistently unfavorable number of CTCs (≥ 5) and only 1 patient had a ≥ 30% PSA decline. Median PFS was 1.9 months (95% confidence interval [CI], 0.9-3.1) and median overall survival (OS) was 8.8 months (95% CI, 3.1-15.6). Toxicities included grade 4 hypophosphatemia and central nervous system (CNS) hemorrhage, and frequent grade 3 fatigue, anemia, stomatitis, hypokalemia, weakness, and hyperglycemia. CONCLUSION: Temsirolimus lacked sufficient clinical activity in men with mCRPC, despite transient CTC improvements in some men. Future studies should focus on combination approaches or novel PI3K pathway inhibitors.
File Format	HTM / HTML
ISSN	15587673
Issue Number	4
Volume Number	11
e-ISSN	19380682
Journal	Clinical Genitourinary Cancer
Language	English
Publisher	Elsevier
Publisher Date	2013-12-01
Publisher Place	United States
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Discipline Urology Discipline Oncology Prostatic Neoplasms, Castration-resistant Drug Therapy Protein Kinase Inhibitors Adverse Effects Therapeutic Use Sirolimus Analogs & Derivatives Adult Aged Bone Neoplasms Secondary Disease Progression Disease-free Survival Humans Male Middle Aged Multiprotein Complexes Antagonists & Inhibitors Neoplastic Cells, Circulating Phosphatidylinositol 3-kinase Prostate-specific Antigen Blood Mortality Survival Tor Serine-threonine Kinases Treatment Failure Clinical Trial, Phase Ii Journal Article Multicenter Study Research Support, Non-u.s. Gov't
Content Type	Text
Resource Type	Article
Subject	Urology Oncology

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Safety and preliminary efficacy analysis of the mTOR inhibitor ridaforolimus in patients with taxane-treated, castration-resistant prostate cancer.

Selective Efficacy of Temsirolimus on Bone Metastases in Chromophobe Renal Cell Carcinoma.

Phase II trial of bevacizumab and satraplatin in docetaxel-pretreated metastatic castrate-resistant prostate cancer.

Lenalidomide monotherapy in chemotherapy-naive, castration-resistant prostate cancer patients: final results of a phase II study.

PSA flare with abiraterone in patients with metastatic castration-resistant prostate cancer.

Clinical phenotypes associated with circulating tumor cell enumeration in metastatic castration-resistant prostate cancer.

Response to subsequent docetaxel in a patient cohort with metastatic castration-resistant prostate cancer after abiraterone acetate treatment.

A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer.

A phase II study of bevacizumab and everolimus as treatment for refractory metastatic renal cell carcinoma.

A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer.

Similar Documents

Safety and preliminary efficacy analysis of the mTOR inhibitor ridaforolimus in patients with taxane-treated, castration-resistant prostate cancer.

Selective Efficacy of Temsirolimus on Bone Metastases in Chromophobe Renal Cell Carcinoma.

Phase II trial of bevacizumab and satraplatin in docetaxel-pretreated metastatic castrate-resistant prostate cancer.

Lenalidomide monotherapy in chemotherapy-naive, castration-resistant prostate cancer patients: final results of a phase II study.

PSA flare with abiraterone in patients with metastatic castration-resistant prostate cancer.

Clinical phenotypes associated with circulating tumor cell enumeration in metastatic castration-resistant prostate cancer.

Response to subsequent docetaxel in a patient cohort with metastatic castration-resistant prostate cancer after abiraterone acetate treatment.

A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer.

A phase II study of bevacizumab and everolimus as treatment for refractory metastatic renal cell carcinoma.

A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer.